AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01403415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT03998956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI+BOX
Description: Circumferential PV and BOX isolation
Study NCT03998956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI+BOX+SUB
Description: Atrial substrate ablation apart from circumferential PV and BOX isolation
Study NCT02421289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: There will be adjusted dose of efavirenz in CYP2B6 guide group
Study NCT02421289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.
Study NCT02421289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP450 2B6
Description: All patients will be monitored drug level which should be in therapeutic level.
Study NCT01403415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01403415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study NCT01403415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT01403415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV
Study NCT01403415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04007445 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Formally Directed Group (Exercise Group)
Description: This group will receive a 12-week exercise intervention that will educate and support the person's ability to exercise. Working with a trainer, the participant will attend a 12-week (3 x week) exercise program that has been personalized to their goals. Each session will include warm-up, stretching, cardiovascular exercises, strength exercises, and cool-down. Each session will be 1-2 hours in duration. The participants may wear accelerometers and heart rate monitors to help determine the level of intensity of the exercises, as they should be performing at least 150 minutes of moderate to vigorous exercise each week. By the end of the 12-week program, the goal is for participants to guide their own exercise regimens.
Study NCT01403415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT01403415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02560012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sunitinib
Description: One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
Study NCT02560012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temsirolimus
Description: 25 mg by an IV infusion over 30-60 minutes, once a week
Study NCT04007445 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self-Directed Group (Control Group)
Description: This group will receive a 1-hour education session during which they will learn about the National Council on Health, Physical Activity and Disability (NCHPAD) website, an information and resource center on health promotion for people with disabilities. During the session participants will be given an overview of the website and asked to find three resources they find of interest. Their strength and fitness will also be assessed by completing a 1-rep max test. The participants will then be asked to maintain their regular physical activity for the next 12 weeks and complete a weekly physical activity log to track their exercise participation. A staff member will phone each person every week for the 12-week period and have the participant report his or her physical activity during the week.
Study NCT04086342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHI-902
Description: A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.
Study NCT00617994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 1.5% cream BID for 28 days
Study NCT05896605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
Study NCT01848925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SANGUINATE™
Description: 40 mg/mL intravenous infusion.
Study NCT01848925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Standard of care for Sickle Cell treatment, 15 mg/kg.
Study NCT01144429 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allergoid, allergenic extract of 100% Birch
Description: Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks
Study NCT02928055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
Study NCT02045901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclegis
Description: On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
Study NCT02045901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sugar Pill)
Description: On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
Study NCT02495662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-liposomal prednisolone sodium phosphate
Description: Liposomal prednisolone
Study NCT02495662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline
Study NCT03348163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/FTC/TAF
Description: B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)
Study NCT03348163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current ART
Description: Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.
Study NCT03203122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPL laser
Description: IPL laser monthly. Vertical and horizontal treatment, one pass over. Settings according to fitzpatrick skin type
Study NCT03203122 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No sham treatment
Description: The treatment is slightly painful, and noisy. Sham treatment impossible
Study NCT02770378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles
Study NCT02770378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles
Study NCT02770378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
Study NCT02770378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
Study NCT02770378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
Study NCT02770378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
Study NCT02560012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: 400 mg (2 tablets) orally twice daily without food
Study NCT02560012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib
Description: 800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
Study NCT02560012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus
Description: 10 mg orally once daily with or without food
Study NCT02560012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Axitinib
Description: 5 mg orally twice daily
Study NCT01921842 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NAP-SACC Child Care Wellness Program
Description: Nutrition And Physical activity Self-Assessment for Child Care
Study NCT01921842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAP-SACC Child Care Wellness Program
Description: Nutrition And Physical activity Self-Assessment for Child Care
Study NCT01798433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One stent technique alone
Description: One stent technique alone with drug-eluting stent
Study NCT04086342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a vehicle oil that will match CHI-902.
Study NCT00255749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Study NCT01798433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One stent technique + Elective FKB
Description: One stent technique + Elective FKB with drug-eluting stents + balloon
Study NCT01798433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Provisional approach
Description: Provisional approach with drung-eluting stents
Study NCT01798433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elective 2-stent
Description: Elective 2-stent with drug-eluting stents
Study NCT04033328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: ORIC-101 once daily in each 28-day cycle
Study NCT03111329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No aspiration of gastric residuals
Description: No assessment of gastric residuals will be performed prior to administering 3-hourly feeds with increasing amounts of the feeds given as per a predefined plan
Study NCT04420663 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pleural Manometry
Description: Recording pleural pressure during therapeutic thoracocentesis using a simple water manometer.
Study NCT01998308 — intervention group
Intervention type: DRUG
Intervention: Crespine gel
Description: 50 Knees will have single injection of Crespine gel
Study NCT01998308 — intervention group
Intervention type: DRUG
Intervention: Intragel
Description: 50 Knees will have single injection of 2 ampules of Intragel
Study NCT02770378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily
Study NCT02770378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
Study NCT04033328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide 40 MG oral capsule [Xtandi]
Description: 160 mg once daily in each 28-day cycle
Study NCT02159495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT02159495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV
Study NCT02159495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02159495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes
Description: Given IV
Study NCT02159495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02770378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily
Study NCT02770378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
Study NCT01937078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo. Each treatment phase will last for 14 days. Doses of drug will be titrated upwards, starting at 40mg once daily on day one, 40mg twice daily on day two, and 80mg twice daily (or placebo + drug equivalent) from day three and then continue on this dose for the next 12 days. Regardless of treatment phase, subjects will take 2 tablets twice daily, with varying ratios of active famotidine to placebo. Thus famotidine 80mg/d will consist of 1 tablet of 40 mg famotidine plus 1 tablet of placebo twice a day; 120 mg /d famotidine will be 2 tablets at 40 mg morning and 1 tablet famotidine 40 mg plus 1 tablet placebo evening; famotidine 160 mg/d will be famotidine 40 mg tablets, 2 tablets twice a day. The placebo phase will consist of 2 placebo tablets twice a day.
Study NCT01777022 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A package of interventions
Description: A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth
Study NCT01240629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT01998308 — intervention group
Intervention type: DRUG
Intervention: Crespine plus gel
Description: 50 Knees will have single injection of Crespine Plus Gel
Study NCT01240629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Correlative study
Study NCT01240629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin-GnRH agonist conjugate AEZS-108
Description: Given IV
Study NCT00617942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 neo-adjuvant
Description: Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14~Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
Study NCT00617942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 neo-adjuvant
Description: Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
Study NCT00617942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 adjuvant
Description: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
Study NCT00617942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 adjuvant
Description: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
Study NCT03521089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001
Description: Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
Study NCT03521089 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001
Description: Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
Study NCT03642002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toning
Description: Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable
Study NCT03642002 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ocean drum & SOK melody
Description: Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable
Study NCT03642002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOK
Description: Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.
Study NCT03642002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process
Description: Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.
Study NCT03642002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holding Harmonic Container
Description: Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment
Study NCT04892095 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational cross-sectional study. No intervention is considered.
Study NCT04235673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: orally administered drops
Study NCT04235673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally administered drops
Study NCT04115904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ibuprofen for post operative pain
Description: All treatment sessions were approximately 45 minutes in length to allow for acceptable time for completionof treatment and retreatment in one or two visits. Allthe clinical procedures were performed by the author.Following local anesthesia with 2% lidocaine with1:100,000 epinephrine (Septodont Saint-Maur desFossés, France) and rubber dam isolation the toothwas disinfected with 5.25% NaOCl (Ultra bleach,Bentonville, AR, USA).
Study NCT01998308 — intervention group
Intervention type: DRUG
Intervention: Monovisc
Description: 50 Knees will have single injection of Monovisc
Study NCT03368846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: \[14C\]-Varlitinib